 |
Email the Society |
 |
Donations |
ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
Mailing address:
GPO Box 383,
Adelaide,
South Australia 5001
Office:
266 Port Road,
Hindmarsh,
South Australia 5007
Ph: (08) 8346 3237
('834 MECFS')
Office Hours:
Wednesdays, 10am-3pm
Support Line:
(Mondays and Thursdays,
10am-3pm)
Ph: (08) 8346 3237
SA country callers:
Ph: 1300 128 339
(local call)
FIBROMYALGIA HELP: Contact Fibromyalgia SA at the Arthritis Foundation of SA 118 Richmond Road, Marleston 5033 Ph: (08) 8379 5711 |
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
|
Disclaimer
ME/CFS Australia (SA) Inc aims to keep members informed of the various research projects, diets, medications, therapies etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
| Become a Member | |||
|
Generic version of Fibromyalgia drug 'tentatively approved'
Friday 10 December 2010
About.com's Adrienne Dellwo reports:
Generic Version of Fibromyalgia Drug 'Tentatively Approved'
NEWSBRIEF: A generic form of the fibromyalgia drug Cymbalta (duloxetine) has received tentative approval from the U.S. FDA. Impax Laboratories sought approval for delayed-release 20, 30 and 60 mg duloxetine capsules.
The agency gives a "tentative approval" when the drug meets all standards but is still under market protection, meaning no one other than the current manufacture can produce and sell it. Eli Lilly will lose that protection in 2013.
This means that Impax can make arrangements to begin selling duloxetine once that protection runs out. Generic versions of medications are usually much less expensive and more likely to be covered by insurance.
Learn more or join the conversation!
NEWSLETTER | FORUM | BIO | TWITTER | FACEBOOK
The above, with comments, originally appeared here.
|
More Fibromyalgia News |
blog comments powered by Disqus
Previous Page |
